Clinical trial
A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for…
NCT00455520 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00455520 |
|---|---|
| Title | A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral Neuropathy |
| Official title | A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of CG5503 Extended Release (ER) in Subjects With Painful Diabetic Peripheral Neuropathy |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Collaborators | Grünenthal GmbH Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetic Neuropathy |
| Intervention type | Drug |
| Interventions | CG5503, placebo |
| Enrollment | 395 |
| Start date | Apr 1, 2007 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Apr 3, 2007 |
| Last update posted | Jul 19, 2013 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: